Bioeq AG is a Swiss biologicaleutical joint venture between Polpharma Biologics Group and the Strüngmann family's investment company. We license, develop and commercialize a biosimilar, which is a successor product of Lucentis® (ranibizumab), a successful branded biopharmaceutical. We are a young and dynamic company, supportedd by an international network of experts.